The CD79B gene is frequently affected by recurrent splice site mutations in DLBCL that frequently lead to intron 4 retention with premature termination of CD79B translation, resulting in BCR overexpression and enhancement of NF-κB and AKT signaling [44]. The gene discussed is CD79B; the disease is diffuse large B-cell lymphoma.